Rabacfosadine

Rabacfosadine
Clinical data
Trade names	TANOVEA-CA1
AHFS/Drugs.com	Veterinary Use
Routes of; administration	Intravenous
ATCvet code	QL01BB90 (WHO) ;
Legal status
Legal status	US: Rx-only, veterinary ;
Identifiers
CAS Number	859209-74-8;
PubChem CID	16047979;
ChemSpider	4486268;
UNII	M39BO43J9W;
KEGG	D10723;
ChEMBL	ChEMBL1823518;
CompTox Dashboard (EPA)	DTXSID10235245 ;
Chemical and physical data
Formula	C11H35N8O6P
Molar mass	406.425 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC(=O)[C@H](C)NP(=O)(COCCN1C=NC2=C1N=C(N=C2NC3CC3)N)N[C@@H](C)C(=O)OCC;
	InChI InChI=1S/C21H35N8O6P/c1-5-34-19(30)13(3)27-36(32,28-14(4)20(31)35-6-2)12-33-10-9-29-11-23-16-17(24-15-7-8-15)25-21(22)26-18(16)29/h11,13-15H,5-10,12H2,1-4H3,(H2,27,28,32)(H3,22,24,25,26)/t13-,14-/m0/s1; Key:ANSPEDQTHURSFQ-KBPBESRZSA-N;

Rabacfosadine, marketed by VetDC under the brand name Tanovea-CA1 (rabacfosadine for injection), is a guanine nucleotide analog used for the treatment of lymphoma in dogs. The drug is conditionally approved by the U.S. Food and Drug Administration under application number 141-475 for use in treating canine lymphoma[1] pending a full demonstration of effectiveness. Originally developed by Gilead Sciences as GS-9219,[2] rabacfosadine is no longer being pursued for use in the treatment of lymphoma in humans.

The active form of rabacfosadine is a chain-terminating inhibitor of the major deoxyribonucleic acid (DNA) polymerases. In vitro studies have demonstrated that rabacfosadine inhibits DNA synthesis, resulting in S phase arrest and induction of apoptosis.[3] It also inhibits the proliferation of lymphocytes in dogs with naturally occurring lymphoma.[4]

Veterinary uses

The FDA label indication is "For the treatment of lymphoma in dogs". Rabacfosadine can be used in dogs with lymphoma new to treatment and in dogs that are no longer responding to conventional chemotherapy. It comes in the form of a sterile, lyophilized powder that is reconstituted and administered as a 30-minute intravenous infusion. Infusions are given once every three weeks for up to five treatments.[5]

Adverse effects

Common side effects of rabacfosadine are decreased white blood cell count, diarrhea, vomiting, decreased appetite or loss of appetite, weight loss, decreased activity level, and skin problems. Other side effects may occur.[1]

References

"FDA Conditionally Approves Tanovea-CA1, the first New Animal Drug for Treating Lymphoma in Dogs". U.S. Food and Drug Administration. January 3, 2017.
De Clercq E (August 2018). "Tanovea® for the treatment of lymphoma in dogs". Biochemical Pharmacology. 154: 265–269. doi:10.1016/j.bcp.2018.05.010. PMID 29778492.
Reiser H, Wang J, Chong L, Watkins WJ, Ray AS, Shibata R, et al. (May 2008). "GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma". Clinical Cancer Research. 14 (9): 2824–32. doi:10.1158/1078-0432.CCR-07-2061. PMID 18451250.
Lawrence J, Vanderhoek M, Barbee D, Jeraj R, Tumas DB, Vail DM (2009). "Use of 3'-deoxy-3'-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma". Veterinary Radiology & Ultrasound. 50 (6): 660–8. doi:10.1111/j.1740-8261.2009.01612.x. PMID 19999354.
"Canine Lymphoma Treatment | TANOVEA For Pet Owners". VetDC. Retrieved 2019-10-02.

External links

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[:0-1] "FDA Conditionally Approves Tanovea-CA1, the first New Animal Drug for Treating Lymphoma in Dogs". U.S. Food and Drug Administration. January 3, 2017.

[2] De Clercq E (August 2018). "Tanovea® for the treatment of lymphoma in dogs". Biochemical Pharmacology. 154: 265–269. doi:10.1016/j.bcp.2018.05.010. PMID 29778492.

[3] Reiser H, Wang J, Chong L, Watkins WJ, Ray AS, Shibata R, et al. (May 2008). "GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma". Clinical Cancer Research. 14 (9): 2824–32. doi:10.1158/1078-0432.CCR-07-2061. PMID 18451250.

[4] Lawrence J, Vanderhoek M, Barbee D, Jeraj R, Tumas DB, Vail DM (2009). "Use of 3'-deoxy-3'-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma". Veterinary Radiology & Ultrasound. 50 (6): 660–8. doi:10.1111/j.1740-8261.2009.01612.x. PMID 19999354.

[5] "Canine Lymphoma Treatment | TANOVEA For Pet Owners". VetDC. Retrieved 2019-10-02.